stockrow
Monday 9 November 2026
Export SPRB’s income statement to Excel — free account
Spruce Biosciences, Inc.
SPRBSpruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023.
- Revenue
- −75.9%
- EPS
- −90.9%
- Free cash flow
- −152.1%
- Total debt
- +427.2%
Quarter to June 2026, against a year earlier
46.55
3.84
+8.99%
Follow SPRB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
8.78 | 4.59 | 4.85 | 1.13 | |
Current Ratio |
9.23 | 4.67 | 5.17 | 1.54 | |
Net Debt/EBITDA |
5.62 | 4.06 | 4.41 | 1.23 | |
Debt/Assets |
6.89% | 11.51% | 0.00% | 3.52% | |
Debt/Equity |
0.08 | 0.19 | 0.00 | 0.10 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.36 | 0.71 | 0.44 | 0.65 | |
Capex/Depreciation |
(0.21) | (0.04) | 0.00 | 0.00 | |
Interest Coverage |
(15.05) | (17.78) | (1,850.00) | (433.11) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(9.10) | (6.36) | (4.87) | (9.44) | |
Capex per Share |
(0.06) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(9.15) | (6.37) | (4.87) | (9.44) | |
Cash per Share |
39.61 | 39.42 | 36.88 | 18.95 | |
Shareholders Equity per Share |
34.44 | 25.25 | 32.06 | 9.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
34.44 | 25.25 | 32.06 | 9.57 | |
Free Cash Flow |
(22.25) | (8.74) | (6.46) | (5.32) | |
Working Capital |
90.19 | 43.25 | 42.03 | 5.09 | |
Capital Expenditures |
(0.13) | (0.01) | — | — | |
Net Current Asset Value |
82.03 | 33.51 | 41.61 | 4.59 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
1.01 | 2.28 | 1.12 | 1.59 | |
Average Assets |
62.34 | 43.91 | 49.12 | 40.21 | |
Average Common Equity |
48.46 | 24.99 | 35.67 | 28.51 |
Columns are period end dates · fundamentals updated 26 Oct 2026